Optimal management of retroperitoneal metastatic nonseminomatous testicular cancer: Toward a better selection between scalpel and needle

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5550-5552

  De Wit, Ronald ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ACUTE HEART INFARCTION; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CANCER SURVIVOR; COMBINATION CHEMOTHERAPY; EDITORIAL; HUMAN; LYMPH NODE DISSECTION; NEEDLE; PRIORITY JOURNAL; RETROPERITONEAL CANCER; SCALPEL; TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROPERITONEAL NEOPLASMS; TESTICULAR NEOPLASMS;

EID: 37649016601     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.8883     Document Type: Editorial

References (14)

1. Donohue JP, Thornhill JA, Foster RS, et al: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation. J Urol 149:237-243, 1993
2. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer impact of patient selection factors on outcome. J Clin Oncol 23:2781-2788, 2005
3. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
4. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
5. Oldenburg J, Alfsen GC, Lien HH, et al: Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21:3310-3317, 2003
6. Horwich A, Stenning S: Initial chemotherapy for stage II testicular nonseminoma. World J Urol 12:148-150, 1994
7. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001
8. Loehrer PJ, Hui S, Clark S, et al: Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: A clinico-pathological correlation. J Urol 135:1183-1189, 1986
9. Mizutani Y, Sato N, Kawauchi A, et al: Cisplatin-induced in vivo differentiation of human embryonal carcinoma. BJU Int 89:454-458, 2002
10. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003
11. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year suvivors of testicular cancer. J Clin Oncol 24:467-475, 2006
12. Travis LB, Fossa SD, Schonfeld SJ, et al: Second cancers among 40.576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005
13. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
14. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Non-randomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage II A and II B nonseminomatous germ cell testicular cancer. J Clin Oncol doi: 10.1200/JCO.2007.12.0808